EOLS compared with VYNE: revenue, margins and what each company keeps, and the suppliers and customers both name

EOLSEvolus, Inc.

Mkt capRevenueRevenue

VYNEVYNE Therapeutics Inc.

Mkt capRevenueRevenue

Compare

EOLSEvolus, Inc.

VYNEVYNE Therapeutics Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

EOLS

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±15.6%▼−9.04%×0.58

Q2 FY26±27.1%▲+19.90%×0.73

May 5 '26±16.7%▲+14.16%×0.85

Q1 FY26±20.2%▲+35.35%×1.75

VYNE

Reportimpliedrealized× implied

Aug 14 '26—▼−0.54%—

Jul 29 '26—▲+8.56%—

Nov 6 '25

= impliedEOLS realized, solidVYNE realized, hatchedOne scale, both sides: full bar = 36%× = |realized| ÷ impliedSource: market data

—

▲+4.59%

—

Aug 14 '25—▲+0.69%—

EOLSEvolus, Inc.

6.82▲+0.38%· post 6.82

Mkt cap$450.4MRevenue$78MQ3 FY26Revenue$297MFY25

VYNEVYNE Therapeutics Inc.

15.49▲+13.93%· post 15.50

ClosedNov 6 '26

Mkt cap—Revenue—Revenue—

Compare

ClosedNov 6 '26

EOLSEvolus, Inc.

VYNEVYNE Therapeutics Inc.

6.82▲+0.38%post 6.82

Price

15.49▲+13.93%post 15.50

$450.4M

Mkt cap

—

Q3 FY26$78M

Revenue

—

FY25$297M

Revenue

—

EOLS6.82▲+0.38%vsVYNE15.49▲+13.93%ClosedNov 6 '26